ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,679Medicare Part D Prescriptions Filled, Including Refills

Rank: 135 out of 1269

$470K Total Retail Price of All Prescriptions

Rank: 172 out of 1269

314 Patients Receiving at Least One Drug in Part D
62%Patients 65 Years and Older
53% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

19% of this provider’s 314 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

9% of this provider’s 314 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

3% of this provider’s 4,463 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
SIMVASTATIN 278 182 1 3
PRAVASTATIN SODIUM 243 172 2 11
LISINOPRIL 217 162 3 1
LEVOTHYROXINE SODIUM 207 104 4 4
ATORVASTATIN CALCIUM 202 118 5 7
METOPROLOL SUCCINATE 153 127 6 13
AMLODIPINE BESYLATE 146 110 7 2
OXYCODONE-ACETAMINOPHEN 141 61 S2 8 44
ATENOLOL 139 82 9 14
TRAMADOL HCL 131 92 10 16
ZOLPIDEM TARTRATE 127 51 11 19
GLYBURIDE-METFORMIN HCL 120 92 R 12 172
OMEPRAZOLE 106 71 13 8
FUROSEMIDE 103 75 14 5
RAMIPRIL 101 59 15 96
CITALOPRAM HBR 100 58 16 21
RANITIDINE HCL 99 59 17 27
OXYCODONE HCL 99 46 S2 17 34
FLUTICASONE PROPIONATE 95 42 19 40
METOPROLOL TARTRATE 94 64 20 6
GABAPENTIN 86 42 21 17
CARISOPRODOL 82 0 R 22 136
DOXYCYCLINE HYCLATE 80 49 23 214
GLIPIZIDE 74 41 24 37
PROAIR HFA 68 20 25 61
DIVALPROEX SODIUM 68 0 25 54
TRAZODONE HCL 67 40 27 36
ALENDRONATE SODIUM 66 25 28 28
AMOX TR-POTASSIUM CLAVULANATE 65 35 29 110
CLOPIDOGREL 65 40 29 32
TRIAMCINOLONE ACETONIDE 62 22 31 131
LOVASTATIN 61 59 32 30
TAMSULOSIN HCL 59 39 33 31
AMLODIPINE BESYLATE-BENAZEPRIL 59 57 33 81
METFORMIN HCL 59 34 33 9
ATENOLOL-CHLORTHALIDONE 58 41 36 163
LISINOPRIL-HYDROCHLOROTHIAZIDE 56 25 37 33
NEXIUM 56 11 37 41
PANTOPRAZOLE SODIUM 55 48 39 18
PREDNISONE 55 39 39 45
CRESTOR 54 23 41 25
TRIAMTERENE-HCTZ 52 41 42 69
TRICOR 50 16 43 152
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 8, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.